MARKET

BDSX

BDSX

BIODESIX INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.680
-0.140
-7.69%
After Hours: 1.680 0 0.00% 16:00 05/16 EDT
OPEN
1.900
PREV CLOSE
1.820
HIGH
1.915
LOW
1.660
VOLUME
97.61K
TURNOVER
0
52 WEEK HIGH
16.40
52 WEEK LOW
1.310
MARKET CAP
66.85M
P/E (TTM)
-1.0672
1D
5D
1M
3M
1Y
5Y
--Morgan Stanley Lowers Biodesix's Price Target to $5 From $7, Maintains Equalweight Rating
MT Newswires · 4d ago
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
BOULDER, Colo., May 12, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical man...
Business Wire · 4d ago
Blue Water Vaccines, Oscar Health top healthcare gainers, Inovio, iTeos lead losers' pack
Gainers: Blue Water Vaccines (BWV) +18%. Oscar Health (OSCR) +13%. Veru (VERU) +10%. Zai Lab (ZLAB) +8%. Better Therapeutics (BTTX) +6%. Losers: Inovio Pharmaceuticals (INO) -32%. iTeos Therapeutics (ITOS) -32%. Arcus Biosciences (RCUS) -28%. Akanda (AKAN)...
Seekingalpha · 5d ago
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Recap: Biodesix Q1 Earnings
  Biodesix (NASDAQ:BDSX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Benzinga · 5d ago
Biodesix Q1 EPS $(0.50) Misses $(0.43) Estimate, Sales $6.50M Beat $6.45M Estimate
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.43) by 16.28 percent. This is a 117.39 percent decrease over losses of $(0.23) per share from the
Benzinga · 5d ago
Biodesix GAAP EPS of -$0.50 misses by $0.08, revenue of $6.55M beats by $0.08M
Biodesix press release (NASDAQ:BDSX): Q1 GAAP EPS of -$0.50 misses by $0.08. Revenue of $6.55M (-77.3% Y/Y) beats by $0.08M. Shares up 12% PM. The company reaffirms FY2022 financial outlook and expects
Seekingalpha · 5d ago
BRIEF-Biodesix Announces First Quarter 2022 Results And Highlights
reuters.com · 5d ago
More
No Data
Learn about the latest financial forecast of BDSX. Analyze the recent business situations of BIODESIX INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
25.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BDSX stock price target is 6.00 with a high estimate of 7.00 and a low estimate of 5.00.
High7.00
Average6.00
Low5.00
Current 1.680
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 45
Institutional Holdings: 4.28M
% Owned: 13.45%
Shares Outstanding: 39.79M
TypeInstitutionsShares
Increased
21
238.58K
New
6
206.32K
Decreased
8
185.80K
Sold Out
7
455.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
-0.58%
Healthcare Providers & Services
+0.63%
Key Executives
Non-Executive Chairman/Independent Director
John Patience
President/Chief Executive Officer/Director
Scott Hutton
Chief Financial Officer/Treasurer/Secretary
Robin Cowie
Chief Accounting Officer
Ryan Siurek
Independent Director
Jean Franchi
Independent Director
Jon Kayyem
Independent Director
Hany Massarany
Independent Director
Jack Schuler
Independent Director
Matthew Strobeck
Independent Director
Charles Watts
No Data
No Data
About BDSX
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Webull offers kinds of Biodesix Inc stock information, including NASDAQ:BDSX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSX stock methods without spending real money on the virtual paper trading platform.